Markus Jensen

1.7k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

Markus Jensen is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Markus Jensen has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in Markus Jensen's work include Monoclonal and Polyclonal Antibodies Research (5 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Markus Jensen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), CAR-T cell therapy research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Markus Jensen collaborates with scholars based in Germany, United States and France. Markus Jensen's co-authors include Michael Hallek, Heinz Mehlhorn, Frank Berthold, Joachim L. Schultze, Alexey Popov, Roman K. Thomas, Elmar Endl, Svenja Debey, Percy A. Knolle and Matthias Kochanek and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Markus Jensen

17 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

2014 438 citations Andrew X. Zhu, Olivier Rosmorduc et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Jensen Germany	10	496	396	349	330	319	17	1.3k
Giovanni Abbadessa United States	24	200 0.4×	264 0.7×	396 1.1×	582 1.8×	91 0.3×	99	1.7k
Masaki Ri Japan	24	446 0.9×	200 0.5×	89 0.3×	576 1.7×	138 0.4×	117	1.9k
Abeer A. Bahnassy Egypt	24	104 0.2×	200 0.5×	490 1.4×	501 1.5×	149 0.5×	89	1.6k
Nicholas Lea United Kingdom	19	270 0.5×	124 0.3×	80 0.2×	228 0.7×	516 1.6×	40	1.6k
Teruaki Sekine Japan	14	611 1.2×	169 0.4×	352 1.0×	570 1.7×	30 0.1×	44	1.5k
Erika A. Eksioglu United States	21	868 1.8×	76 0.2×	98 0.3×	381 1.2×	149 0.5×	47	1.7k
Tadahiro Kajita Japan	7	726 1.5×	112 0.3×	268 0.8×	1.1k 3.3×	44 0.1×	9	1.8k
Jobst Greeve Germany	21	312 0.6×	112 0.3×	173 0.5×	238 0.7×	74 0.2×	41	1.8k
Marie‐Françoise Bourgeade France	23	474 1.0×	60 0.2×	103 0.3×	379 1.1×	116 0.4×	46	1.5k
Gertraud Fröschl Austria	15	193 0.4×	131 0.3×	137 0.4×	269 0.8×	55 0.2×	17	1.3k

Countries citing papers authored by Markus Jensen

Since Specialization

Citations

This map shows the geographic impact of Markus Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Jensen more than expected).

Fields of papers citing papers by Markus Jensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Jensen. The network helps show where Markus Jensen may publish in the future.

Co-authorship network of co-authors of Markus Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Jensen. A scholar is included among the top collaborators of Markus Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Jensen. Markus Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sen, Shiraj, Alexander I. Spira, Martin Gutierrez, et al.. (2025). A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Willmann, Stefan, Alexander Solms, Markus Jensen, et al.. (2021). PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics & Systems Pharmacology. 10(8). 890–901. 36 indexed citations

Pimenta, Eduardo, Markus Jensen, David Jung, et al.. (2017). Abstract 15196: A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study. Circulation. 1 indexed citations

Jensen, Markus, et al.. (2016). Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study. Journal of Clinical Medicine Research. 8(11). 836–839. 18 indexed citations

Zhu, Andrew X., Olivier Rosmorduc, T.R. Jeffry Evans, et al.. (2014). SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 33(6). 559–566. 438 indexed citations breakdown →

Böldicke, Thomas, et al.. (2013). Construction, expression and binding specificity of bispecific CD3 × VEGFR-2 and CD3 × NCAM antibodies in the single chain and diabody format. Advances in Bioscience and Biotechnology. 4(5). 654–664. 1 indexed citations

Jensen, Markus & Heinz Mehlhorn. (2009). Seventy-five years of Resochin® in the fight against malaria. Parasitology Research. 105(3). 609–627. 77 indexed citations

Koehl, Ulrike, Martina Mühlenhoff, Samir Tawadros, et al.. (2009). The Novel Chimeric Anti-NCAM (Neural Cell Adhesion Molecule) Antibody ch.MK1 Displays Antitumor Activity in SCID Mice but Does not Activate Complement-Dependent Cytolysis (CDC). Journal of Immunotherapy. 32(5). 442–451. 8 indexed citations

Jensen, Markus, Sandra Schmitz, Samir Tawadros, et al.. (2007). One Step Generation of Fully Chimeric Antibodies Using Cγ1- and Cκ Mutant Mice. Journal of Immunotherapy. 30(3). 338–349. 2 indexed citations

10.

Jensen, Markus & Frank Berthold. (2007). Targeting the neural cell adhesion molecule in cancer. Cancer Letters. 258(1). 9–21. 66 indexed citations

11.

Jensen, Markus, Andreas Engert, Florian Weißinger, et al.. (2007). Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Investigational New Drugs. 26(2). 139–149. 22 indexed citations

12.

Otto, Christina, Markus Jensen, Markus Dietlein, et al.. (2006). Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice. Nuclear Medicine Communications. 27(2). 171–178. 4 indexed citations

13.

Elter, Thomas, Peter Borchmann, H. Schulz, et al.. (2005). Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial. Journal of Clinical Oncology. 23(28). 7024–7031. 153 indexed citations

14.

Beyer, Marc, Matthias Kochanek, Kamruz Darabi, et al.. (2005). Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 106(6). 2018–2025. 395 indexed citations

15.

Jensen, Markus, Samir Tawadros, Hans-Harald Sedlacek, Joachim L. Schultze, & Frank Berthold. (2004). NK cell depletion diminish tumour-specific B cell responses. Immunology Letters. 93(2-3). 205–210. 6 indexed citations

16.

Hombach, Andreas, Markus Jensen, Claudia Heuser, et al.. (1997). Specific Activation of Resting T Cells Against CA19–9+ Tumor Cells by an Anti-CD3/CA19–9 Bispecific Antibody in Combination with a Costimulatory Anti-CD28 Antibody. Journal of Immunotherapy. 20(5). 325–333. 15 indexed citations

17.

Jensen, Markus, et al.. (1996). Breaking of B cell tolerance toward a highly conserved self protein. The Journal of Immunology. 157(11). 4796–4804. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact